UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity
UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now. On February 6, UniQure reported positive updated data from its Phase I/IIa trial of AMT-191, which is a gene therapy for Fabry disease. All 11 patients across three different dose levels showed increased enzyme activity, with the longest-treated patient maintaining these high levels for over a year. Notably, the enzyme levels were significantly above normal ranges, showing a clear relationship between the dose received and the amount of enzyme produced.
The treatment allowed 6 out of the 11 patients to stop their regular enzyme replacement therapy/ERT after meeting specific clinical criteria. Even after stopping ERT, patients maintained stable levels of lyso-Gb3, the toxic substance that typically builds up in Fabry disease. This suggests that the one-time gene therapy could potentially replace the need for lifelong, bi-weekly infusions for some patients.
While the therapy shows promise, UniQure has paused new dosing in the mid- and high-dose groups to evaluate some safety findings. Two patients in the middle dose group experienced high liver enzyme levels that were classified as dose-limiting toxicities, though both responded to steroid treatment. Other previously reported serious events in the high-dose group included chest pain and a stroke, though some were determined to be unrelated to the study drug.
UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI Recovery Targets $1 Reclaim Before Next Rally
Dow Jones Industrial Average bounces on Iran's latest Hormuz offer
U.S. stocks opened higher and fluctuated, the Japanese yen rebounded more than 1% intraday, 10-year U.S. Treasury yields broke above 5.22% again, and U.S. crude oil once fell nearly 3%.
After the release of U.S. consumer confidence data, the S&P and Nasdaq turned negative, while the Dow is poised to break a three-day losing streak but is set for a fourth consecutive weekly decline. Meta pulled back, falling more than 3% during the session. The U.S. 10-year Treasury yield surpassed 5.22% again, marking a new high for the third day in a row since 2007, while the 30-year yield reached its highest level since 2004. The yen/dollar pair surged 1.2% intraday, as Japanese and U.S. officials successively signaled concerns over the weak yen. Expectations for a diplomatic resolution between the U.S. and Iran are rising, halting crude oil's two-day climb.
US Treasury volatility surges, triggering alarms! BofA’s Hartnett warns of rising deleveraging risks as higher yields become main threat to the market
Bank of America strategist Michael Hartnett warns that the recent sharp rise in volatility in the US bond market is increasing the risk of broader deleveraging in financial markets.
Crypto prices
More
